Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer.

Oncotarget · 2014 · PMC4253418 · PMID 24979294

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

failed to reach significanceno p-value reported

Dasatinib monotherapy decreased invasion, however, this failed to reach significance likely due to the small sample size.

also in 4,113 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.